Article Details

Novartis expands in cardiovascular disease with $1.4bn Tourmaline Bio acquisition

Retrieved on: 2025-09-09 12:25:47

Tags for this article:

Click the tags to see associated articles and topics

Novartis expands in cardiovascular disease with $1.4bn Tourmaline Bio acquisition. View article details on hiswai:

Excerpt

... monoclonal antibody that is being tested as a monthly and quarterly treatment option. ... Antibodies, Big Pharma, Biologics, business news ...

Article found on: www.europeanpharmaceuticalreview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo